Skip to content

BioCryst Pharmaceuticals

US · BCRX #2766 by market cap Listed 1970
7.22 -0.10 -1.37%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
  • Total institutional ownership fell 0.6 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
104.07% -0.56pp
Institutions
378 -2
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund55.07%
Hedge Fund21.78%
VC/PE Fund17.08%
Public Company5.52%
Private Company2.31%
Government Pension Fund1.16%
Insurance Company0.93%
Individual/Insider0.89%
Family Office/Trust0.18%

Top holders as of 2026-09-30

BlackRock 9.46% · 24.33M sh
RA Capital Management, L.P. 6.15% · 15.83M sh
Deerfield Management Company, L.P. 5.87% · 15.10M sh
State Street Global Advisors 4.78% · 12.29M sh
Vanguard Capital Management, LLC 4.38% · 11.27M sh
TCG Crossover Management, LLC 4.28% · 11.02M sh
Vanguard Portfolio Management, LLC 4.09% · 10.53M sh
Perceptive Advisors LLC 4.01% · 10.31M sh
Janus Henderson Group plc 3.71% · 9.54M sh
Vestal Point Capital, LP 3.23% · 8.30M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 38 buys · 9 sells

NameRoleStake
Jon Stonehouse Director 0.40%
Charles Gayer Chief Executive Officer 0.14%
Anthony Doyle Former Chief Financial Officer 0.08%
Helen Thackray Former Chief Research & Development Officer 0.06%
Alane Barnes Chief Legal Officer 0.06%
Vincent Milano Independent Chairperson 0.04%
Steven K. Galson Independent Director 0.02%
Theresa Heggie Independent Director 0.02%
Alan Levin Independent Director 0.02%
Ronald Dullinger Chief Commercial Officer 0.02%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-08-30 Vincent Milano Independent Chairperson Other Acquisition +1,159 $9.70
2026-08-30 Steve Frank Independent Director Other Acquisition +1,288 $9.70
2026-08-30 Jill Milne Independent Director Other Acquisition +1,288 $9.70
2026-08-30 Jon Stonehouse Director Other Acquisition +644 $9.70
2026-08-30 Amy McKee Independent Director Other Acquisition +644 $9.70
2026-06-10 Vincent Milano Independent Chairperson Other Acquisition +15,294 --
2026-06-10 Vincent Milano Independent Chairperson Other Derivative Acquisition +33,540 $8.50
2026-06-10 Alan Levin Independent Director Other Acquisition +15,294 --
2026-06-10 Alan Levin Independent Director Other Derivative Acquisition +33,540 $8.50
2026-06-10 Steve Frank Independent Director Other Acquisition +15,294 --
2026-06-10 Steve Frank Independent Director Other Derivative Acquisition +33,540 $8.50
2026-06-10 Jill Milne Independent Director Other Acquisition +15,294 --
2026-06-10 Jill Milne Independent Director Other Derivative Acquisition +33,540 $8.50
2026-06-10 Theresa Heggie Independent Director Other Acquisition +15,294 --
2026-06-10 Theresa Heggie Independent Director Other Derivative Acquisition +33,540 $8.50
2026-06-10 Jon Stonehouse Director Other Acquisition +15,294 --
2026-06-10 Jon Stonehouse Director Other Derivative Acquisition +33,540 $8.50
2026-06-10 Steven K. Galson Independent Director Other Acquisition +15,294 --
2026-06-10 Steven K. Galson Independent Director Other Derivative Acquisition +33,540 $8.50
2026-06-10 A. Sanders Independent Director Other Acquisition +15,294 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.

BioCryst Pharmaceuticals discussion 0 comments

Add a comment